Immunome initiated with an Outperform at Wedbush

Wedbush analyst David Nierengarten initiated coverage of Immunome with an Outperform rating and $12 price target. The firm has a positive view for Immunome’s early-stage pipeline of targeted cancer therapies, including immunotherapies, targeted effectors, radioligand therapies, and antibody-drug conjugates. Beyond internal program development, Immunome is positioned to capitalize on strategic in-licensing and acquisitions driven by the company’s discovery engines, Wedbush adds.